{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:03:44Z","timestamp":1779671024117,"version":"3.53.1"},"reference-count":68,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This study aimed to identify the risk factors of primary cutaneous melanomas associated with microsatellites, satellites, and in-transit metastases. Materials and Methods: We performed a retrospective study on patients diagnosed with invasive primary cutaneous melanomas in two pathology departments. The cases were distributed into two groups, comparing the clinical\u2013pathological features of cases that presented microsatellites, satellites, and in-transit metastases with cases that did not present microsatellites, satellites, and in-transit metastases. Results: From the total number of primary invasive cutaneous melanomas diagnosed (n = 204), 22% presented microsatellites, satellites, and in-transit metastases (n = 46). The presence of microsatellites, satellites, and in-transit metastases was strongly correlated with a Breslow index &gt; 4 mm, a Clark level of IV or V, and a pT3 or pT4 pathological stage (p &lt; 0.0001). Those cases were also associated with lymphovascular invasion (p = 0.0013), ulceration of the primary melanoma (p = 0.0037), and an increased mitotic rate (p = 0.0078). The presence of microsatellites, satellites, and in-transit metastases is associated with higher rates of lymph node metastases (p = 0.0006) and recurrence (p = 0.0282). Conclusions: The most important risk factors associated with microsatellites, satellites, and in-transit metastases are represented by a Breslow index &gt; 4 mm, a Clark level of IV or V, and an advanced pathological stage.<\/jats:p>","DOI":"10.3390\/medicina62061015","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:30:33Z","timestamp":1779669033000},"page":"1015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Risk Factors Correlated with Satellites and In-Transit Metastases in Primary Cutaneous Melanomas"],"prefix":"10.3390","volume":"62","author":[{"given":"Bianca Roxana","family":"Natar\u00e2\u015f","sequence":"first","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-2756","authenticated-orcid":false,"given":"Sorina Maria","family":"T\u0103ban","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-795X","authenticated-orcid":false,"given":"Aura","family":"Jurescu","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-9437","authenticated-orcid":false,"given":"Octavia Cornelia","family":"Vi\u0163a","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remus Florin","family":"Cornea","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Hurmuz","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7072-6083","authenticated-orcid":false,"given":"Adelina","family":"Vidac","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daciana","family":"Grujic","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-2792","authenticated-orcid":false,"given":"Valentin Tudor","family":"Popa","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alis Liliana Carmen","family":"Dema","sequence":"additional","affiliation":[{"name":"Anapatmol Research Centre, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timi\u015foara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"ref_1","unstructured":"SEER (2026, February 03). Melanoma of the Skin\u2014Cancer Stat Facts. SEER Web Site, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_2","unstructured":"Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN ESITMates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-4632.2012.05635.x","article-title":"Patterns of skin metastases: A review of 25years\u2019 experience at a single cancer center","volume":"53","author":"Wong","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_7","first-page":"472","article-title":"Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","unstructured":"Amin, M.B., and Edge, S.B. (2017). Melanoma of the Skin. AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/000313481408001233","article-title":"Scalp melanoma and in-transit metastases: A retrospective case-controlled study","volume":"80","author":"Teng","year":"2014","journal-title":"Am. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00000658-198107000-00019","article-title":"Malignant Melanoma Prognostic Significance of \u201cMsicroscopic Satellites\u201d in the Reticular Dermis and Subcutaneous Fat","volume":"194","author":"Day","year":"1981","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archsurg.1989.01410090061014","article-title":"Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal Metastases The most important determinant of survival for patients","volume":"124","author":"Calabro","year":"1989","journal-title":"Arch. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1997.15.3.1039","article-title":"Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system","volume":"15","author":"Buzaid","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJMe068147","article-title":"Sentinel-node biopsy in melanoma","volume":"355","author":"Balch","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/DSS.0000000000001643","article-title":"Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes","volume":"45","author":"Bann","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2005.10.012","article-title":"In-transit\/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection","volume":"42","author":"Rutkowski","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bjps.2005.12.002","article-title":"Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?","volume":"59","author":"Cerovac","year":"2006","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/ASO.2005.08.012","article-title":"A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma","volume":"12","author":"Thompson","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/bjs.4692","article-title":"High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma","volume":"91","author":"Estourgie","year":"2004","journal-title":"Br. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ejso.2004.04.004","article-title":"Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local\/in-transit recurrence in malignant melanoma","volume":"30","author":"Thomas","year":"2004","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","first-page":"207","article-title":"Risk Factors for In-transit Metastasis in Patients with Cutaneous Melanoma","volume":"103","year":"2012","journal-title":"Actas Dermo-Sifiliogr. Engl. Ed."},{"key":"ref_27","unstructured":"Noone, A.M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2018). SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Weide, B., Faller, C., B\u00fcttner, P., Pflugfelder, A., Leiter, U., Eigentler, T.K., Bauer, J., Forschner, A., Meier, F., and Garbe, C. (2013). Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063137"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1245\/s10434-025-17084-4","article-title":"Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma","volume":"32","author":"Huibers","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2022.06.010","article-title":"Primary cutaneous melanoma features predict development of in-transit metastases\/satellite lesions: Mayo Clinic experience, 2010 to 2014","volume":"88","author":"Kumar","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","first-page":"40","article-title":"Prognostic factors for in-transit metastasis in patients with malignant melanoma","volume":"95","author":"Roman","year":"2022","journal-title":"Med. Pharm. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4068\/cmj.2017.53.3.234","article-title":"The \u2018All-or-None Law\u2019 Applied to the Vertical Growth Phase of Cutaneous Malignant Melanoma","volume":"53","author":"Roncati","year":"2017","journal-title":"Chonnam Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann. Surg."},{"key":"ref_34","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41379-020-0500-9","article-title":"The prognostic significance of microsatellites in cutaneous melanoma","volume":"33","author":"Niebling","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","article-title":"Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database","volume":"29","author":"Thompson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1309\/G6EK-Y6EH-0LGY-6D6P","article-title":"Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma: A Study of Interobserver Agreement","volume":"115","author":"Busam","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CCO.0b013e328337fe8f","article-title":"The biology behind prognostic factors of cutaneous melanoma","volume":"22","author":"Spatz","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model Predicting Survival in Stage I Melanoma Based on Tumor Progression","volume":"81","author":"Clark","year":"1989","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archsurg.1991.01410360031006","article-title":"The Prognostic Implications of Microscopic Satellites in Patients With Clinical Stage I Melanoma","volume":"126","author":"Daly","year":"1991","journal-title":"Arch. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12659\/MSM.905862","article-title":"Regression and sentinel lymph node status in melanoma progression","volume":"24","author":"Letca","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00262-015-1726-0","article-title":"Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas","volume":"64","author":"Fu","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jnci\/86.10.761","article-title":"Clinical and Histopathologic Predictors of Survival in Patients With Malignant Melanoma: A Population-Based Study in Sweden","volume":"86","author":"Thorn","year":"1994","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/labinvest.2017.8","article-title":"Regression in primary cutaneous melanoma: Etiopathogenesis and clinical significance","volume":"97","author":"Aung","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ijc.1491","article-title":"Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A\/MART-1","volume":"94","author":"Saleh","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0000000000000211","article-title":"Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy","volume":"26","author":"Fogarty","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1245\/ASO.2005.03.074","article-title":"Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy","volume":"12","author":"Yee","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vi\u021ba, O., Jurescu, A., V\u0103duva, A., Cornea, R., Cornianu, M., T\u0103ban, S., Szilagyi, D., Mic\u0219escu, C., Natar\u00e2\u0219, B., and Dema, A. (2023). Invasive Cutaneous Melanoma: Evaluating the Prognostic Significance of Some Parameters Associated with Lymph Node Metastases. Medicina, 59.","DOI":"10.3390\/medicina59071241"},{"key":"ref_49","first-page":"1533","article-title":"Local Melanoma Recurrence: A Clarification of Terminology","volume":"30","author":"Maccormack","year":"2004","journal-title":"Dermatol. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jso.20079","article-title":"The natural course of cutaneous melanoma","volume":"86","author":"Leiter","year":"2004","journal-title":"J. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1096-9098(199804)67:4<228::AID-JSO4>3.0.CO;2-A","article-title":"Factors Affecting Survival Following Local, Regional, or Distant Recurrence From Localized Melanoma","volume":"67","author":"Soong","year":"1998","journal-title":"J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2133.1999.02657.x","article-title":"A rational approach to melanoma follow-up in patients with primary cutaneous melanoma","volume":"140","author":"Dicker","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1529-8019.2005.00049.x","article-title":"Cutaneous melanoma: Surveillance of patients for recurrence and new primary melanomas","volume":"18","author":"Oseitutu","year":"2005","journal-title":"Dermatol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am. J. Dermatopathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1529-8019.2005.00055.x","article-title":"Distinguishing melanocytic nevi from melanoma by DNA copy number changes: Comparative genomic hybridization as a research and diagnostic tool","volume":"19","author":"Bauer","year":"2006","journal-title":"Dermatol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41379-020-0490-7","article-title":"Through the looking glass and what you find there: Making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis","volume":"33","author":"Miedema","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mrgentox.2010.06.011","article-title":"Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma","volume":"702","author":"Figl","year":"2010","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jso.23559","article-title":"Local and regional therapies for melanoma: Many arrows in the quiver","volume":"109","author":"Thompson","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in Cutaneous Melanoma: Is There Still a Role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u2013positive advanced melanoma: Extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cbt.28555","article-title":"Melanoma immunotherapy","volume":"15","author":"Sanlorenzo","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_66","unstructured":"National Cancer Institute (2026, February 04). Melanoma Treatment (PDQ\u00ae)\u2013Health Professional Version, Available online: https:\/\/www.cancer.gov\/types\/skin\/hp\/melanoma-treatment-pdq."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-017-1328-z","article-title":"Management and potentialities of primary cancer cultures in preclinical and translational studies","volume":"15","author":"Miserocchi","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9BM01766F","article-title":"Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma","volume":"8","author":"Molinaro","year":"2020","journal-title":"Biomater. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:00:58Z","timestamp":1779670858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061015"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061015","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}